Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;18(3):230-3.
doi: 10.1016/j.parkreldis.2011.10.006. Epub 2011 Oct 21.

Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale

Sydney E Seidel  1 , Barbara C Tilley, Peng Huang, Yuko Y Palesch, Kenneth J Bergmann, Christopher G Goetz, Christopher J Swearingen
Affiliations

Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale

Sydney E Seidel et al. Parkinsonism Relat Disord. 2012 Mar.

Abstract

Objective: To evaluate the subject-investigator agreement on the Unified Parkinson's Disease Rating Scale (UPDRS) subsections I and II.

Methods: Subject-investigator agreement was estimated at baseline and endpoint by Kappa statistics for individual items and concordance correlations for subscale totals using data from two NIH Exploratory Trials in Parkinson's Disease studies.

Results: All but two questions had moderate subject-investigator agreement at baseline and endpoint. Participants consistently rated their disease activity worse that investigators.

Conclusion: UPDRS self-administration produces similar results to investigator-administration. Although slightly elevated, UPDRS self-administration can be accommodated in a clinical trial setting.

PubMed Disclaimer

Conflict of interest statement

The authors confirm that they have no conflicts of interest related to this research. The views presented in this article do not necessarily reflect those of the Food and Drug Administration. No official support or endorsement of this article by the Food and Drug Administration is intended or should be inferred.

Figures

Figure 1
Figure 1
Observed Agreement at Baseline and Final Outcome for UPDRS-I, UPDRS-II and Combined Subscale Total
See this image and copyright information in PMC

References

    1. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002;17(5):867–76. - PubMed
    1. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson’s Disease Rating Scale motor examination. Mov Disord. 1994;9(1):89–91. - PubMed
    1. Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I, et al. Test-retest reliability of the Unified Parkinson’s disease Rating Scale in participants with early Parkinson’s disease: Results from a multicenter clinical trial. Mov Disord. 2002;17(4):758–63. - PubMed
    1. Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses’ ratings of parkinsonian signs with a modified Unified Parkinson’s Disease Rating Scale. Neurology. 1997;49(6):1580–7. - PubMed
    1. Post B, Merkus MP, de Bie RM, de Haan RJ, Speelman JD. Unified Parkinson’s disease rating scale motor examination: Are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable? Mov Disord. 2005;20(12):1577–84. - PubMed

Publication types